Current Report Filing (8-k)
March 22 2018 - 5:29PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): March 16, 2018
PROPANC
BIOPHARMA, INC.
(Exact
name of registrant as specified in its charter)
Delaware
|
|
000-54878
|
|
33-0662986
|
(State
or other Jurisdiction
of Incorporation)
|
|
(Commission
File Number)
|
|
(IRS
Employer
Identification No.)
|
302,
6 Butler Street
Camberwell,
VIC, 3124 Australia
|
|
|
(Address
of Principal Executive Offices)
|
|
(Zip
Code)
|
Registrant’s
telephone number, including area code:
61 03 9882 6723
(Former
name or former address, if changed since last report.)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
[ ]
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
[ ]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company [ ]
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
Item
5.02
|
Departure
of Directors or Certain Officers, Election of Directors; Appointment of Certain Officers,
Compensatory Arrangements of Certain Officers
|
On
March 16, 2018, the Board of Directors (the “Board”) of Propanc Biopharma, Inc. (the “Company”)
approved an increase of AU$100,000 (US$77,328.33) in the annual base salary of James Nathanielsz, the Company’s Chief Executive
Officer, from AU$300,000 (US$231,984.99) to AU$400,000 (US$309,313.32), effective immediately. In addition, having reviewed the
Company’s corporate objectives and performance criteria, including performance goals for Mr. Nathanielsz, the Board awarded
a cash bonus of AU$300,000 (US$231,984.99) to Mr. Nathanielsz, which is equal to 100% of his annual base salary in 2017,
and is consistent with the bonus parameters set forth in Mr. Nathanielsz’s existing employment agreement with Company.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
Propanc
Biopharma, Inc.
|
|
|
|
Date:
March 22, 2018
|
By:
|
/s/
James Nathanielsz
|
|
|
James
Nathanielsz
|
|
|
Chief
Executive Officer, Chief Financial Officer and Chief Accounting Officer
|
Propanc Biopharma (PK) (USOTC:PPCB)
Historical Stock Chart
From Mar 2024 to Apr 2024
Propanc Biopharma (PK) (USOTC:PPCB)
Historical Stock Chart
From Apr 2023 to Apr 2024